News

P-BCMA-101 Clinical Data Presented at CAR-TCR Summit

Poseida Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma Poseida Therapeutics Inc. – a clinical-stage biotechnology company translating best-in-class gene engineering technologies into lifesaving cell therapies – announced data results from the first eleven patients treated in its ongoing Phase 1 study of its…

Details

Myeloma UK is helping to Make Blood Cancer Visible this September

Myeloma UK is helping to Make Blood Cancer Visible in September. The campaign, in partnership with Janssen Oncology and eight patient organisations, marks Blood Cancer Awareness Month. It will feature a public art installation, which will help visitors to understand the experiences of people affected by blood cancer.   The installation is made up of…

Details

Darzalex gains EU approval for new frontline combination treatment

Janssen has announced EU approval of Darzalex (daratumumab) for use alongside Takeda’s Velcade (bortezomib), melphalan and prednisone (VMP) for newly diagnosed myeloma patients who are ineligible for high-dose chemotherapy and autologous stem cell transplant (ASCT). The approval is based on results of the ALCYONE clinical trial which showed that adding Darzalex to VMP reduces the risk of…

Details

Prophylactic antibiotic combination reduces incidence of infection following ASCT

Results from a retrospective study have shown that prophylactic treatment with doxycycline and ciprofloxacin reduces the incidence of infection in myeloma patients following an autologous stem cell transplant (ASCT), when compared to treatment with ciprofloxacin alone. Published in Supportive Cancer Care, the results show that 53% of patients receiving ciprofloxacin alone developed neutropenic fever compared…

Details